Balanced regulation of the CCN family of matricellular proteins: a novel approach to the prevention and treatment of fibrosis and cancer

Treatment with the Matricellular Protein CCN3 Blocks and/or Reverses Fibrosis Development in Obesity with Diabetic Nephropathy

(2014) Bruce L. Riser et al.   AMERICAN JOURNAL OF PATHOLOGY

New strategy to control cell migration and metastasis regulated by CCN2/CTGF

(2014) Diego Aguiar et al.   Cancer Cell International

Patients with Encapsulating Peritoneal Sclerosis Have Increased Peritoneal Expression of Connective Tissue Growth Factor (CCN2), Transforming Growth Factor-β1, and Vascular Endothelial Growth Factor

(2014) Alferso C. Abrahams et al.   PLoS One

CCN2 plays a key role in extracellular matrix gene expression in severe hypertrophic cardiomyopathy and heart failure

(2013) Tatiana Tsoutsman et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Nephrogenic Systemic Fibrosis

(2012) Brent Wagner et al.   AMERICAN JOURNAL OF PATHOLOGY

New Experimental Models of Diabetic Nephropathy in Mice Models of Type 2 Diabetes: Efforts to Replicate Human Nephropathy

(2012) María José Soler et al.   Experimental Diabetes Research

Adenoviral CCN3/NOV gene transfer fails to mitigate liver fibrosis in an experimental bile duct ligation model because of hepatocyte apoptosis

(2012) Erawan Borkham-Kamphorst et al.   LIVER INTERNATIONAL

Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis

(2012) Bruce L. Riser et al.   Journal of Cell Communication and Signaling

Anti-fibrotic effect of CCN3 accompanied by altered gene expression profile of the CCN family

(2012) Tarek Abd El Kader et al.   Journal of Cell Communication and Signaling

Stimulation of Fibroblast Proliferation by Insoluble Gadolinium Salts

(2011) Katherine Bleavins et al.   BIOLOGICAL TRACE ELEMENT RESEARCH

Effects of Antiproteinuric Intervention on Elevated Connective Tissue Growth Factor (CTGF/CCN-2) Plasma and Urine Levels in Nondiabetic Nephropathy

(2011) M. C. J. Slagman et al.   Clinical Journal of the American Society of Nephrology

Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases

(2011) Jeffrey L. Barnes et al.   KIDNEY INTERNATIONAL

Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets

(2011) Joon-Il Jun et al.   NATURE REVIEWS DRUG DISCOVERY

CCN3/NOV small interfering RNA enhances fibrogenic gene expression in primary hepatic stellate cells and cirrhotic fat storing cell line CFSC

(2011) Erawan Borkham-Kamphorst et al.   Journal of Cell Communication and Signaling

CCN3 Inhibits Neointimal Hyperplasia Through Modulation of Smooth Muscle Cell Growth and Migration

(2010) Tatsushi Shimoyama et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Responses of Human Skin in Organ Culture and Human Skin Fibroblasts to a Gadolinium-Based MRI Contrast Agent

(2010) Marissa DaSilva et al.   INVESTIGATIVE RADIOLOGY

Fibroblast Response to Gadolinium

(2010) Narasimharao Bhagavathula et al.   INVESTIGATIVE RADIOLOGY

BTBR Ob/Ob Mutant Mice Model Progressive Diabetic Nephropathy

(2010) K. L. Hudkins et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

The Role of Tumor Stroma in Cancer Progression and Prognosis: Emphasis on Carcinoma-Associated Fibroblasts and Non-small Cell Lung Cancer

(2010) Roy M. Bremnes et al.   Journal of Thoracic Oncology

CCN3/CCN2 regulation and the fibrosis of diabetic renal disease

(2010) Bruce L. Riser et al.   Journal of Cell Communication and Signaling

CCN3 (NOV) Is a Negative Regulator of CCN2 (CTGF) and a Novel Endogenous Inhibitor of the Fibrotic Pathway in an in Vitro Model of Renal Disease

(2009) Bruce L. Riser et al.   AMERICAN JOURNAL OF PATHOLOGY

Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents

(2009) Peter J. Wermuth et al.   ARTHRITIS AND RHEUMATISM

Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy

(2009) Frederick W.K. Tam et al.   CYTOKINE

Effects of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents on Human Skin in Organ Culture and Human Skin Fibroblasts

(2009) James Varani et al.   INVESTIGATIVE RADIOLOGY

Regulation of Collagen Turnover in Human Skin Fibroblasts Exposed to a Gadolinium-Based Contrast Agent

(2009) Narasimharao Bhagavathula et al.   INVESTIGATIVE RADIOLOGY

Collagenolytic Activity Is Suppressed in Organ-Cultured Human Skin Exposed to a Gadolinium-Based MRI Contrast Agent

(2009) Patricia A. Perone et al.   INVESTIGATIVE RADIOLOGY

Scleromyxedema with an interstitial granulomatous-like pattern: a rare histologic variant mimicking granuloma annulare

(2009) Franco Rongioletti et al.   JOURNAL OF CUTANEOUS PATHOLOGY

Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis

(2009) E. Kovalenko et al.   JOURNAL OF VIRAL HEPATITIS

CCN3: a key growth regulator in Chronic Myeloid Leukaemia

(2009) Lynn McCallum et al.   Journal of Cell Communication and Signaling

Matricellular proteins: an overview

(2009) Paul Bornstein   Journal of Cell Communication and Signaling

Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions

(2008) Martin A. Sieber et al.   EUROPEAN RADIOLOGY

The CCN family of proteins: structure–function relationships

(2008) Kenneth P. Holbourn et al.   TRENDS IN BIOCHEMICAL SCIENCES

CCN3 is a novel endogenous PDGF-regulated inhibitor of glomerular cell proliferation

(2007) C.R.C. van Roeyen et al.   KIDNEY INTERNATIONAL

Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice

(2007) H. Yokoi et al.   KIDNEY INTERNATIONAL